ReviewTrends in pharmacological sciences2021
Biological Cells as Therapeutic Delivery Vehicles.
Review in Trends in pharmacological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Artificial "zombie" cells: An emerging platform for targeted drug delivery and disease treatment.Acta pharmaceutica Sinica. B · 2026Review
- Human Multi-Organ-on-a-Chip Platforms for Next-Generation Drug Delivery Strategies.Theranostics · 2026Review
- Photo-Empowered Macrophage-Based Drug Delivery System Overcomes Motility Suppression and Significantly Enhances Deep Tumor Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An engineered yeast cytosine deaminase with improved catalytic activity and stability for macrophage-mediated enzyme/prodrug therapy.Communications biology · 2025Article
- Effects of super-activated platelet lysate and bone mesenchymal stem cells on bone regeneration, and expression of bone metabolism-related factors in rats.Cell and tissue banking · 2025Article
- Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.International journal of molecular sciences · 2025Review
- Technology Roadmap of Micro/Nanorobots.ACS nano · 2025Review
- Programming megakaryocytes to produce engineered platelets for delivering non-native proteins.Communications biology · 2025Article
- Platelet hitchhiking vascular-disrupting agents for self-amplified tumor-targeting therapy.Journal of nanobiotechnology · 2025Article
- NIR-Programmed Trimodal Macrophage Nanovectors for Effective Anti-Tumor Therapy in Mice Model.International journal of nanomedicine · 2025Article
- Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform 'cold' tumors into 'hot' tumors.Molecular cancer · 2024Review
- Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.Current medical science · 2024Review
- Macrophage based drug delivery: Key challenges and strategies.Bioactive materials · 2024Review
- Advancing in vivo reprogramming with synthetic biology.Current opinion in biotechnology · 2024Review
- Genetically engineered mesenchymal stem cells as a nitric oxide reservoir for acute kidney injury therapy.eLife · 2023Article
- Evolution of molecular switches for regulation of transgene expression by clinically licensed gluconate.Nucleic acids research · 2023Article
- Hybrid Lymphatic Drug Delivery Vehicles as a New Avenue for Targeted Therapy: Lymphatic Trafficking, Applications, Challenges, and Future Horizons.The Journal of membrane biology · 2023Review
- Proteomes of Micro- and Nanosized Carriers Engineered from Red Blood Cells.Journal of proteome research · 2023Article
- Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges.Pharmaceutics · 2023Review
- Probing cell membrane integrity using a histone-targeting protein nanocage displaying precisely positioned fluorophores.Nano research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
One of the significant challenges remaining in the field of drug delivery is insufficient targeting of diseased tissues or cells. While efforts to perform targeted drug delivery by engineered nanoparticles have shown some success, there are underlying targeting, toxicity, and immunogenicity challenges. By contrast, live cells usually have innate targeting mechanisms, and can be used as drug-delivery vehicles to increase the efficiency with which a drug accumulates to act on the intended tissue. In some cases, when no native cell types exhibit the desired therapeutic phenotype, preferred outcomes can be achieved by genetically modifying and reprogramming cells with gene circuits. This review highlights recent advances in the use of cells to deliver therapeutics. Specifically, we discuss how red blood cells (RBCs), platelets, neutrophils, mesenchymal stem cells (MSCs), and bacteria have been utilized to advance drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.